While early salvage immunotherapy remains an attractive approach for resected high-risk melanoma, a secondary analysis of a phase 3 trial evaluating adjuvant pembrolizumab versus placebo for resected stage IIB/IIC melanoma points to a novel advantage of blanket early post-operative immunotherapy: a significant decrease in the rate of subsequent non-melanoma skin cancers. | Leachman, JAMA Netw Open 2026
